PwC's Next in Health
Co -hosted by Glenn Hunzinger, US Health Industries leader, and Jennifer Colapietro, Consulting Commercial Leader, the Next in Health podcast series offers insights on the most important issues facing pharma, medtech and healthcare. PwC business leaders discuss the latest trends and their impact on health industries, whether it’s policy, AI, innovation, care delivery, business model reinvention or bold moves for the future. If it’s happening in health industries, we’re talking about it.
PwC's Next in Health
Navigating Healthcare’s Next Chapter Under the Trump Administration
Disclaimer: This episode was recorded on April 11th, 2025, and reflects the information available at the time of recording. As we know, America is in motion here, and so subsequent updates may not be reflected in this discussion as things continue to evolve and change.
Tune in as PwC specialists from across the health industry share their insights on how recent policy shifts under the Trump administration could shape healthcare in the years to come. In this episode, Glenn Hunzinger, Jenny Colapietro, and guests Kelly Griffin, Phil Sclafani, and Ruchita Kewalramani break down the potential implications of proposed government healthcare cuts, tariff policy and agency workforce reductions, along with the growing role of AI in the industry. They also discuss how pharma, medtech, payers and providers can stay ahead amidst the uncertainty. Discussion highlights:
- Proposed funding cuts to major government healthcare programs like Medicare, Medicaid, and NIH could significantly disrupt access, affordability, and service delivery across the healthcare landscape.
- Workforce reductions at federal agencies like the Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), and Health and Human Services (HHS) may slow drug approvals, diminish oversight, and impact public health standards.
- New and evolving tariff policies are creating cost pressures across pharmaceutical and medtech supply chains, with potential downstream impacts on pricing, R&D, and patient access.
- The rapid adoption of AI in healthcare is creating new opportunities across diagnostics, R&D, and operations, while also raising concerns around governance and data privacy.
- To stay ahead, industry leaders must assess risks, strengthen agility, and uncover opportunities to innovate in today’s dynamic environment.
Speakers:
Kelly Griffin, Director, Health Policy Intelligence Institute, PwC
Ruchita Kewalramani, Partner, Health Services PwC
Phil Sclafani, Partner, Pharma & Life Sciences, PwC
Glenn Hunzinger, Partner, Health Industries Leader, PwC
Jenny Colapietro, Principal, Consulting Commercial Leader, PwC
Linked materials:
Health Policy and Intelligence Institute
For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.